EGFR and non-small cell lung carcinoma: Osimertinib’s approval for this indication was initially based on the AURA trial and subsequently on the FLAURA trial, a phase 3 trial that compared osimertinib to first-generation EGFR-TKIs and showed an overall response rate (ORR) of 80%, median progression-free survival (PFS) of 18.9 months, and median overall survival (mOS) of 38.6 months in untreated EGFR-mutated NSCLC patients.